Please use this identifier to cite or link to this item:
https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9008
Title: | Perioperative Lymphopenia is Associated with Increased Risk of Recurrence and Worse Survival Following Hepatectomy for Hepatocellular Carcinoma |
Authors: | Tsilimigras, D. I.;Endo, Y.;Ratti, F.;Marques, H. P.;Cauchy, F.;Lam, Vincent W. T.;Poultsides, G. A.;Popescu, I.;Alexandrescu, S.;Martel, G.;Kitago, M.;Guglielmi, A.;Hugh, T.;Aldrighetti, L.;Gleisner, A.;Shen, F.;Endo, I.;Pawlik, T. M. |
WSLHD Author: | Lam, Vincent W. T. |
Issue Date: | 2024 |
Citation: | Annals of Surgical Oncology 31(4):2568-2578, 2024 |
Abstract: | INTRODUCTION: Immune dysregulation may be associated with cancer progression. We sought to investigate the prognostic value of perioperative lymphopenia on short- and long-term outcomes among patients undergoing resection of hepatocellular carcinoma (HCC).METHODS: Patients undergoing resection of HCC between 2000 and 2020 were identified using an international database. The incidence and impact of perioperative lymphopenia [preoperative, postoperative day (POD) 1/3/5], defined as absolute lymphocyte count (ALC) <1000/muL, on short- and long-term outcomes was assessed.RESULTS: Among 1448 patients, median preoperative ALC was 1593/muL [interquartile range (IQR) 1208-2006]. The incidence of preoperative lymphopenia was 14.0%, and 50.2%, 45.1% and 35.6% on POD1, POD3 and POD5, respectively. Preoperative lymphopenia predicted 5-year overall survival (OS) [lymphopenia vs. no lymphopenia: 49.1% vs. 66.1%] and 5-year disease-free survival (DFS) [25.0% vs. 41.5%] (both p < 0.05). Lymphopenia on POD1 (5-year OS: 57.1% vs. 71.2%; 5-year DFS: 30.0% vs. 41.1%), POD3 (5-year OS: 57.3% vs. 68.9%; 5-year DFS: 35.4% vs. 42.7%), and POD5 (5-year OS: 53.1% vs. 66.1%; 5-year DFS: 32.8% vs. 42.3%) was associated with worse long-term outcomes (all p < 0.05). Patients with severe lymphopenia (ALC <500/muL) on POD5 had worse 5-year OS and DFS (5-year OS: 44.7% vs. 54.3% vs. 66.1%; 5-year DFS: 27.8% vs. 33.3% vs. 42.3%) [both p < 0.05], as well as higher incidence of overall (45.5% vs. 25.3% vs. 30.9%; p = 0.013) and major complications (18.2% vs. 3.4% vs. 4.5%; p < 0.001) versus individuals with moderate (ALC 500-1000/muL) or no lymphopenia following hepatectomy for HCC. After adjusting for competing risk factors, prolonged lymphopenia was independently associated with higher hazards of death [hazard ratio (HR) 1.38, 95% CI 1.11-1.72] and recurrence (HR 1.22, 95% CI 1.02-1.45). CONCLUSION: Perioperative lymphopenia had short- and long-term prognostic implications among individuals undergoing hepatectomy for HCC. Copyright � 2024. Society of Surgical Oncology. |
URI: | https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9008 |
DOI: | https://dx.doi.org/10.1245/s10434-023-14811-7 |
Journal: | Annals of Surgical Oncology |
Type: | Journal Article |
Department: | Surgery |
Facility: | Westmead |
Keywords: | Carcinoma, Hepatocellular Hepatectomy Liver Neoplasms Retrospective Studies Lymphopenia |
Appears in Collections: | Westmead Hospital 2019 - 2024 |
Files in This Item:
There are no files associated with this item.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.